Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.

Tang J, Tu S, Lin G, Guo H, Yan C, Liu Q, Huang L, Tang N, Xiao Y, Pope RM, Rajaram MVS, Amer AO, Ahmer BM, Gunn JS, Wozniak DJ, Tao L, Coppola V, Zhang L, Langdon WY, Torrelles JB, Lipkowitz S, Zhang J.

J Exp Med. 2020 Apr 6;217(4). pii: e20182091. doi: 10.1084/jem.20182091.

PMID:
31999304
2.

Wideband microwave electro-optic image rejection mixer.

Lipkowitz ST, Horton TU, Murphy TE.

Opt Lett. 2019 Oct 1;44(19):4710-4713. doi: 10.1364/OL.44.004710.

PMID:
31568423
3.

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox.

Lim B, Greer Y, Lipkowitz S, Takebe N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1087. doi: 10.3390/cancers11081087. Review.

4.

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM.

J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

5.

Loss of function Cbl-c mutations in solid tumors.

Daniels SR, Liyasova M, Kales SC, Nau MM, Ryan PE, Green JE, Lipkowitz S.

PLoS One. 2019 Jul 1;14(7):e0219143. doi: 10.1371/journal.pone.0219143. eCollection 2019.

6.

Cbl interacts with multiple E2s in vitro and in cells.

Liyasova MS, Ma K, Voeller D, Ryan PE, Chen J, Klevit RE, Lipkowitz S.

PLoS One. 2019 May 23;14(5):e0216967. doi: 10.1371/journal.pone.0216967. eCollection 2019.

7.

HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.

Schardt JS, Noonan-Shueh M, Oubaid JM, Pottash AE, Williams SC, Hussain A, Lapidus RG, Lipkowitz S, Jay SM.

AAPS J. 2019 Apr 4;21(3):48. doi: 10.1208/s12248-019-0318-x.

PMID:
30949858
8.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

9.

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.

Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S.

Breast Cancer Res. 2019 Feb 18;21(1):27. doi: 10.1186/s13058-019-1116-1.

10.

ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S.

Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6.

11.

Update on PARP Inhibitors in Breast Cancer.

Zimmer AS, Gillard M, Lipkowitz S, Lee JM.

Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Review.

PMID:
29644491
12.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
13.

Analysis of breast cancer in young women in the Department of Defense (DOD) database.

Zimmer AS, Zhu K, Steeg PS, Wu A, Gatti-Mays ME, Soltani S, Perkins JG, Shao S, Brown D, Georg M, Hu H, Shriver CD, Lipkowitz S.

Breast Cancer Res Treat. 2018 Apr;168(2):501-511. doi: 10.1007/s10549-017-4615-8. Epub 2017 Dec 15.

14.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

15.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

16.

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM.

Mol Pharm. 2017 Apr 3;14(4):1047-1056. doi: 10.1021/acs.molpharmaceut.6b00919. Epub 2017 Mar 8.

17.

Mathematical models of breast and ovarian cancers.

Botesteanu DA, Lipkowitz S, Lee JM, Levy D.

Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):337-62. doi: 10.1002/wsbm.1343. Epub 2016 Jun 3. Review.

18.

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Yang SX, Polley E, Lipkowitz S.

Cancer Treat Rev. 2016 Apr;45:87-96. doi: 10.1016/j.ctrv.2016.03.004. Epub 2016 Mar 9. Review.

PMID:
26995633
19.

ONC201: Stressing tumors to death.

Endo Greer Y, Lipkowitz S.

Sci Signal. 2016 Feb 16;9(415):fs1. doi: 10.1126/scisignal.aad7955. Review.

PMID:
26884598
20.

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S.

Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12.

Supplemental Content

Loading ...
Support Center